Revisión narrativa de la terapia inhalatoria en la EPOC-Reference-Cited by-同舟云学术

Revisión narrativa de la terapia inhalatoria en la EPOC

Published:2021-09 Issue: Volume: Page:
ISSN:1138-3593
Container-title:Medicina de Familia. SEMERGEN
language:es
Short-container-title:Medicina de Familia. SEMERGEN

Author:

Aguilar-Shea A.L.,Gallardo-Mayo C.

Publisher

Elsevier BV

Subject

Family Practice,Public Health, Environmental and Occupational Health

Reference56 articles.

1. Global initiative for chronic Obstructive Lung Disease (GOLD) [homepage on the internet] Global Strategy for the Diagnosis, Management and Prevention of COPD [2021 REPORT] [consultado 3 Jun 2021]. Disponible en: http://www.goldcopd.org/

2. Spanish COPD Guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD;Miravitlles;Arch Bronconeumol (Engl Ed).,2021

3. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal

4. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD;Wedzicha;N Engl J Med.,2016

5. Long-acting muscarinic antagonist +long-acting beta agonist versus long-acting beta agonist +inhaled corticosteroid for COPD: A systematic review and meta-analysis;Horita;Respirology.,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protocolo de manejo de pacientes con enfermedad pulmonar obstructiva crónica tras agudización en urgencias;Medicina de Familia. SEMERGEN;2023-09